An ethno-bridging study of Pergoveris in healthy premenopausal participants of Japanese or Caucasian
Research type
Research Study
Full title
A Phase 1, open label, single dose, parallel-group study to investigate the pharmacokinetics of the fixed combination of 900 IU r hFSH and 450 IU r hLH given as Pergoveris®, administered subcutaneously in pituitary-suppressed healthy premenopausal female participants of Japanese or Caucasian origins
IRAS ID
1012476
Contact name
Communication Center Merck KGaA
Contact email
Sponsor organisation
Merck Healthcare KGaA
Clinicaltrials.gov Identifier
Research summary
Pergoveris is a fixed combination product consisting of r hFSH and r hLH - synthetic forms of two hormones FSH (follicle stimulating hormone) and LH (luteinising hormone) - in a ratio 2:1, for the stimulation of follicular development in women with severe LH and FSH deficiency. Disorders leading to reduced LH and FSH may lead to the absence of adequate ovulation, resulting in infertility and anovulation is estimated to account for up to 24% of human infertility problems. This is a Phase 1, open-label, single dose, parallel-group study where a fixed combination of 900 IU r hFSH and 450 IU r hLH given as Pergoveris, administered subcutaneously (an injection under the skin) in premenopausal female participants of Japanese or Caucasian origin. Prior to dosing, the participants are administered the combined oral contraceptive Marvelon. This suppresses the pituitary (a gland at the base of the brain) such that the hormones aren’t produced naturally, a process called downregulation.
The aim of this ethno-bridging study is to investigate the levels in the blood of both r-hFSH and r-hLH in Caucasian and Japanese participants to address any potential ethnic effect and to support the registration of Pergoveris solution for injection in a prefilled pen in Japan.
Approximately 24 (12 Japanese, 12 Caucasian) healthy female participants, meeting the eligibility criteria after confirming downregulation, will receive a single dose of Pergoveris on Day 1. The group of Caucasian participants will be matched by mean body weight (± 20% body weight [kg]) and mean age (± 10 years) to the group of Japanese participants as assessed at Day 1.
The study duration is approximately 9 weeks. Participants will visit the clinic once during screening period, twice during the 4-week downregulation period and will stay in the clinical research unit from Day -1 until the end of the study on Day 8.REC name
London - Harrow Research Ethics Committee
REC reference
25/LO/0542
Date of REC Opinion
1 Oct 2025
REC opinion
Further Information Favourable Opinion